PM
IMRX icon

Prosight Management’s Immuneering IMRX Stock Holding History

Prosight Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$650K Buy
+123,409
New +$633K 0.11% 42
2024
Q4 		– Sell
-190,000
Closed -$473K – 41
2024
Q3 		$473K Sell
190,000
-360,000
-65% -$524K 0.12% 43
2024
Q2 		$704K Buy
+550,000
New +$904K 0.21% 44

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prosight Management's IMRX Position: Q1 2026 in Review

Prosight Management opened a new position in Immuneering (IMRX) in Q1 2026: 123,409 shares worth $650K. The stake represents 0.11% of the portfolio and ranks #42 among its holdings. This is a return to the name: Prosight Management previously reported a position in IMRX as recently as Q3 2024.

Prosight Management first reported a position in IMRX in Q2 2024 and has held it in 3 quarters since. The position peaked at $704K in Q2 2024. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Prosight Management held 123,409 shares of Immuneering worth $650K as of Q1 2026.
  • Immuneering was a new Prosight Management position in Q1 2026.
  • Immuneering made up 0.11% of Prosight Management's portfolio in Q1 2026, its #42 holding.
  • Prosight Management first reported a position in Immuneering in Q2 2024 and has held it in 3 quarters since.
  • Prosight Management's Immuneering position peaked at $704K in Q2 2024.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.